Form 4: Insmed CEO William Lewis Reports Stock Sales and Option Exercise
SEC Form 4 Filing
William Lewis, Chair and CEO of Insmed Inc, reports the sale of common stock and exercise of stock options on April 1, 2025, according to a pre-arranged 10b5-1 trading plan.
Summary
- William Lewis, the Chair and CEO of Insmed Inc., filed a Form 4 detailing changes in beneficial ownership.
- On April 1, 2025, Lewis executed transactions involving Insmed's common stock and stock options.
- Lewis exercised stock options to acquire 6,830 shares at a price of $10.85 per share.
- He also sold shares of common stock at weighted average prices ranging from $72.29 to $75.26.
- These transactions were conducted under a pre-arranged 10b5-1 trading plan.
- Following these transactions, Lewis directly owns 334,186 shares of common stock.
- Lewis indirectly owns 233,924 shares through the Katie Procter Dynasty Trust and 50,500 shares through the William Lewis Family Legacy Trust.
- He also indirectly owns 184,480 derivative securities (stock options) through the Katie Procter Dynasty Trust.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's prospects.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and potential future actions.
Comparison to Industry Standards
- Monitoring insider transactions is a standard practice in the pharmaceutical industry, similar to how investors track filings from executives at companies like Vertex Pharmaceuticals or BioMarin Pharmaceutical.
- The use of 10b5-1 trading plans is also common among executives to avoid accusations of insider trading, mirroring practices seen at companies such as Amgen and Gilead Sciences.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan suggests no significant change in management's outlook.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of stock option exercise and stock sales. |
| 04/03/2025 | Date of Form 4 filing. |
| 05/19/2026 | Expiration date of stock options. |
Keywords
Form 4, Insmed, William Lewis, Stock Options, Stock Sale, Beneficial Ownership, 10b5-1 Trading Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.